Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer

Table 2 Correlations between age group and clinicopathological features, including EGFR status

	No. of patients
Characteristics	Total	≥80 years	<80 years	p ^a
	(n = 388)	(n = 29, 7.5%)	(n = 359, 92.5%)
Mean age, yr ± SD^b	66.6 ± 10.0	82.6 ± 2.41	65.3 ± 9.29	<0.001
Gender				0.246
Male	228	20	208
Female	160	9	151
Histology				0.034
Adenocarcinoma	302	18	284
others	86	11	75
Biomarker
EGFR wild type	203	22	181	0.008
EGFR mutation	185	7	178
KRAS wild type	355	23	332	0.014
KRAS mutation	33	6	27
Vascular invasion
Ly -	314	26	288	0.214
Ly +	74	3	71
V -	261	18	243	0.535
V +	127	11	116
p-stage				0.080
I	293	18	275
II / III	95	11	84
T-factor				0.506
T1	197	13	184
T2/3	191	16	175
Tumor diameter (cm)	3.03 ± 1.43	3.00 ± 1.44	3.40 ± 1.24	0.629
N-factor				0.584
N0	322	23	299
N1/2	66	6	60
Operation				0.155
Limited resection (wedge/segmentectomy)	80	3	77
Standard surgery (lobectomy, pneumonectomy)	308	26	282
Lymph node resection				<0.001
ND0/1/sampling	109	25	156
ND2	278	4	203
Smoking				0.024
Non-smoker	157	6	151
Smoker	231	23	208
Pre-existing cardiopulmonary comorbidity	203	21	182	0.024

^ap < 0.05 statistically significant.
^bSD, standard deviation.
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ND, lymph node dissection.

ISSN: 1471-2407